Cited 14 times in
Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신재일 | - |
dc.contributor.author | 이금화 | - |
dc.date.accessioned | 2018-07-20T08:33:56Z | - |
dc.date.available | 2018-07-20T08:33:56Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0306-9877 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161287 | - |
dc.description.abstract | Henoch-Schönlein Purpura (HSP, IgA vasculitis) is an immunoglobulin A (IgA) mediated disorder characterized by systemic vasculitis with variable presentation, frequently affecting the skin, mucous membrane, joints, kidneys, and rarely lungs and the central nervous system. Interestingly, enhanced production of interleukin-8 (IL-8) levels are found during active disease and increased levels have been reported in supernatants from human umbilical venous endothelial cells after stimulation with sera from patients affected by HSP. While corticosteroid therapy is currently the recommended treatment for HSP, dapsone, an anti-leprosy agent, has also recently been suggested to have therapeutic efficacy due to its ability to suppress IL-8. Moreover, in addition to IL-8 suppression, dapsone has been reported to exert various anti-inflammatory effects by inhibiting the generation of toxic free radicals, myeloperoxidase mediated halogenation that converts H2O2 to HOCl, leukocyte chemotaxis, production of tumor necrosis factor, and other anti-inflammatory molecules. This review aims to provide a solid hypothesis for the pathogenesis of vasculitis in HSP. Moreover, we highlight potential mechanistic actions of dapsone in hopes that dapsone may be considered as an alternative viable treatment for patients affected by HSP. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Eden Press | - |
dc.relation.isPartOf | MEDICAL HYPOTHESES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Dapsone as a potential treatment option for Henoch-Schönlein Purpura (HSP) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Pediatrics | - |
dc.contributor.googleauthor | Keum Hwa Lee | - |
dc.contributor.googleauthor | Jae Hyon Park | - |
dc.contributor.googleauthor | Dong Hyun Kim | - |
dc.contributor.googleauthor | Ji min Hwang | - |
dc.contributor.googleauthor | Go eun Lee | - |
dc.contributor.googleauthor | Jae Seok Hyun | - |
dc.contributor.googleauthor | Sung Taik Heo | - |
dc.contributor.googleauthor | Ji Hoon Choi | - |
dc.contributor.googleauthor | Min woo Kim | - |
dc.contributor.googleauthor | Min hye Kim | - |
dc.contributor.googleauthor | Seong Il Kim | - |
dc.contributor.googleauthor | Michael Eisenhut | - |
dc.contributor.googleauthor | Andreas Kronbichler | - |
dc.contributor.googleauthor | Jae Il Shin | - |
dc.identifier.doi | 10.1016/j.mehy.2017.07.018 | - |
dc.contributor.localId | A02142 | - |
dc.contributor.localId | A04622 | - |
dc.relation.journalcode | J02200 | - |
dc.identifier.eissn | 1532-2777 | - |
dc.identifier.pmid | 29055398 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0306987717304814 | - |
dc.subject.keyword | Dapsone | - |
dc.subject.keyword | Henoch-Schönlein Purpura (HSP) | - |
dc.subject.keyword | Immunoglobulin A (IgA) | - |
dc.subject.keyword | Interleukin-8 (IL-8) | - |
dc.subject.keyword | Small vessel vasculitis | - |
dc.contributor.alternativeName | Shin, Jae Il | - |
dc.contributor.alternativeName | Lee, Geum Hwa | - |
dc.contributor.affiliatedAuthor | Shin, Jae Il | - |
dc.contributor.affiliatedAuthor | Lee, Geum Hwa | - |
dc.citation.volume | 108 | - |
dc.citation.startPage | 42 | - |
dc.citation.endPage | 45 | - |
dc.identifier.bibliographicCitation | MEDICAL HYPOTHESES, Vol.108 : 42-45, 2017 | - |
dc.identifier.rimsid | 61209 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.